AIM ImmunoTech (AIM) News Today $2.52 -0.03 (-0.98%) As of 01:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AIM Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Head-To-Head Analysis: AIM ImmunoTech (NYSE:AIM) vs. Alpha Cognition (OTC:ACOGF)August 23, 2025 | americanbankingnews.comAIM ImmunoTech releases CEO Corner segmentAugust 22, 2025 | msn.comAIM ImmunoTech Announces Release of the Next CEO Corner SegmentAugust 21, 2025 | globenewswire.comCritical Review: Big Cypress Acquisition (OTCMKTS:BCYP) versus AIM ImmunoTech (NYSE:AIM)August 21, 2025 | americanbankingnews.comAIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 15, 2025 | globenewswire.comUncovering Potential: AIM ImmunoTech's Earnings PreviewAugust 14, 2025 | benzinga.comAIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTechAugust 14, 2025 | globenewswire.comAIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research ...August 12, 2025 | theglobeandmail.comAIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)August 6, 2025 | globenewswire.comAIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer ApprovalAugust 4, 2025 | globenewswire.comAIM ImmunoTech Closes $8 Million Public OfferingAugust 1, 2025 | msn.comAIM ImmunoTech Announces Closing of $8.0 Million Public OfferingJuly 31, 2025 | finance.yahoo.comAIM ImmunoTech Inc.: AIM ImmunoTech Announces Pricing of $8.0 Million Public OfferingJuly 30, 2025 | finanznachrichten.deAIM ImmunoTech Shares Drop After $8 Million Offering PricedJuly 30, 2025 | marketwatch.comAIM ImmunoTech reports Ampligen combo trial data for pancreatic cancerJuly 30, 2025 | msn.comAIM ImmunoTech Announces Pricing of $8.0 Million Public OfferingJuly 30, 2025 | finance.yahoo.comAIM IMMUNOTECH INC COM Insider Trading ActivityJuly 29, 2025 | benzinga.comAIM ImmunoTech Shares Climb on Positive Data From Ongoing Phase Two StudyJuly 29, 2025 | marketwatch.comWhy Is Micro-Cap AIM ImmunoTech Stock Surging?July 28, 2025 | benzinga.comAIM ImmunoTech Reports Positive Phase 2 Study ResultsJuly 28, 2025 | tipranks.comAIM ImmunoTech Inc. Showcases Ampligen Research at U.S.-Poland Science and Technology Symposium 2025 - NasdaqJuly 3, 2025 | nasdaq.comAIM ImmunoTech Inc. (AIM) - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comAIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology TherapiesJuly 2, 2025 | globenewswire.comAIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders’ Equity RequirementsJune 20, 2025 | finance.yahoo.comAIM ImmunoTech Faces NYSE Noncompliance NotificationJune 20, 2025 | tipranks.comAIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity RequirementsJune 20, 2025 | globenewswire.comAIM ImmunoTech (NYSE:AIM) Shares Gap Up - Should You Buy?June 20, 2025 | marketbeat.comAIM ImmunoTech (NYSE:AIM) Trading Down 15.5% - Time to Sell?June 18, 2025 | marketbeat.comAIM ImmunoTech (NYSE:AIM) Sets New 1-Year High - Here's WhyJune 17, 2025 | marketbeat.comAIM ImmunoTech Resumes Trading on NYSE AmericanJune 17, 2025 | globenewswire.comAIM ImmunoTech granted U.S. patent for AmpligenJune 12, 2025 | msn.comAIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®June 12, 2025 | globenewswire.comAIM ImmunoTech Announces NYSE American Removal of Trading SuspensionJune 12, 2025 | globenewswire.comAIM ImmunoTech Inc.: AIM ImmunoTech Announces 1-for-100 Reverse Stock SplitJune 12, 2025 | finanznachrichten.deAIM ImmunoTech Announces 1-for-100 Reverse Stock SplitJune 11, 2025 | globenewswire.comAIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of ImmunologistsMay 8, 2025 | globenewswire.comAIM ImmunoTech Inc AIMIApril 19, 2025 | morningstar.comMAIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open MarketApril 7, 2025 | globenewswire.comAIM ImmunoTech Inc trading halted, news pendingApril 5, 2025 | markets.businessinsider.comNYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM)April 4, 2025 | businesswire.comAIM ImmunoTech Announces NYSE American Notice of Delisting and AppealApril 4, 2025 | globenewswire.comAIM ImmunoTech Inc. (AMEX:AIM) Q4 2024 Earnings Call TranscriptApril 3, 2025 | msn.comQ4 2024 AIM ImmunoTech Inc Earnings CallApril 2, 2025 | finance.yahoo.comAIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Call TranscriptApril 1, 2025 | seekingalpha.comAIM ImmunoTech made ‘significant strides’ over course of 2024March 27, 2025 | markets.businessinsider.comEarnings Preview For AIM ImmunoTechMarch 27, 2025 | benzinga.comAIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 27, 2025 | markets.businessinsider.comAIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand ConferenceMarch 11, 2025 | globenewswire.comInsider Buying: AIM ImmunoTech Inc. (NYSE:AIM) CEO Acquires 83,334 Shares of StockMarch 5, 2025 | insidertrades.comAIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenzaFebruary 28, 2025 | globenewswire.com Get AIM ImmunoTech News Delivered to You Automatically Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AIM Media Mentions By Week AIM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AIM News Sentiment▼0.001.03▲Average Medical News Sentiment AIM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AIM Articles This Week▼22▲AIM Articles Average Week Get the Latest News and Ratings for AIM and Related Stocks Enter your email address to receive the latest news and analysts' ratings for AIM ImmunoTech and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies BCLI News ACXP News KZIA News MBIO News ARTL News APM News ALZN News PLRZ News SBFM News CDIO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:AIM) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIM ImmunoTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access